{"title":"口服托法替尼治疗难治性外阴阴道扁平苔藓。","authors":"Benetta Benny, Anupama Bains, Aasma Nalwa","doi":"10.1111/ajd.14403","DOIUrl":null,"url":null,"abstract":"<p><p>Erosive vulvovaginal lichen planus is a severe form of Lichen planus (LP) that can result in chronic scarring if not treated. It can cause narrowing of the introitus, resulting in pain, itch, dyspareunia, dysuria, and recurrent urinary tract infections caused by retention of urine. Therefore, an effective and safer therapeutic approach is required. Here, we present a case of refractory erosive vulvovaginal LP, which showed remarkable response to oral tofacitinib, a Janus kinase 1 and 3 (JAK1/3) inhibitor, which was well tolerated.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Refractory Vulvovaginal Lichen Planus Responding to Oral Tofacitinib.\",\"authors\":\"Benetta Benny, Anupama Bains, Aasma Nalwa\",\"doi\":\"10.1111/ajd.14403\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Erosive vulvovaginal lichen planus is a severe form of Lichen planus (LP) that can result in chronic scarring if not treated. It can cause narrowing of the introitus, resulting in pain, itch, dyspareunia, dysuria, and recurrent urinary tract infections caused by retention of urine. Therefore, an effective and safer therapeutic approach is required. Here, we present a case of refractory erosive vulvovaginal LP, which showed remarkable response to oral tofacitinib, a Janus kinase 1 and 3 (JAK1/3) inhibitor, which was well tolerated.</p>\",\"PeriodicalId\":8638,\"journal\":{\"name\":\"Australasian Journal of Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajd.14403\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.14403","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Refractory Vulvovaginal Lichen Planus Responding to Oral Tofacitinib.
Erosive vulvovaginal lichen planus is a severe form of Lichen planus (LP) that can result in chronic scarring if not treated. It can cause narrowing of the introitus, resulting in pain, itch, dyspareunia, dysuria, and recurrent urinary tract infections caused by retention of urine. Therefore, an effective and safer therapeutic approach is required. Here, we present a case of refractory erosive vulvovaginal LP, which showed remarkable response to oral tofacitinib, a Janus kinase 1 and 3 (JAK1/3) inhibitor, which was well tolerated.
期刊介绍:
Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.